Novonesis (Novozymes) B (LTS:0Q4U) Net Change in Cash : kr274 Mil (TTM As of Mar. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Novonesis (Novozymes) B Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Novonesis (Novozymes) B's Net Change in Cash for the three months ended in Mar. 2025 was kr-227 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was kr274 Mil.

Novonesis (Novozymes) B Net Change in Cash Historical Data

The historical data trend for Novonesis (Novozymes) B's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Net Change in Cash Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

469.89

-217.97

77.88

74.54

971.74

Novonesis (Novozymes) B Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															67.08	470.49	358.25	143.19	-227.49

Novonesis (Novozymes) B Net Change in Cash Calculation

Novonesis (Novozymes) B's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	7606.104	+	-1489.302	+	-5244.252	+	99.187
	=	972

Novonesis (Novozymes) B's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 793.606 + -285.668 + -761.534 + 26.105

= -227

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr274 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (LTS:0Q4U) » Definitions » Net Change in Cash

Comparable Companies

OCSE:SPG OCSE:FLUG B OCSE:HOVE LIN XPAR:AI SHW ECL APD XSWX:GIVN ISX:TPIA XSWX:SIKA XAMS:DSFIR DD BOM:500820 SHSE:600309 PPG ADX:BOROUGE IFF LYB NSE:PIDILITIND

Traded in Other Exchanges

NVZMY:USA NVZMF:USA NSISBc:UK NSIS B:Denmark NZM:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines